Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 12 of the 17 sources its claims cite were checked for support.

High-throughput human microfluidic organoid-on-a-chip platform for modeling liver diseases and screening nanotherapeutics.

Open access

Abstract

We combined healthy human liver tissue-derived organoids with a high-throughput three-lane OrganoPlate microfluidic format to establish a perfused organoid Liver-on-Chip (HepLoC) featuring 3D luminal tubules under continuous flow... As a proof-of-concept for drug-induced liver injury, troglitazone induced dose-dependent hepatocyte injury... To model metabolic liver disease, free fatty acids triggered lipid droplet accumulation...

Overview

CoChat Summary

TL;DR

The paper builds a high-throughput human liver organoid-on-a-chip (HepLoC) by integrating healthy human liver tissue–derived organoids into a perfused OrganoPlate microfluidic system. HepLoC forms mature hepatocyte-like tubules with functional bile canaliculi and is used to model troglitazone-induced cholestasis, free-fatty-acid–induced early MAFLD features, and to screen nanotherapeutics.

Key findings

  • Organoid-derived cells self-organized into 3D luminal tubules in chip after about 1 week of dynamic culture, and FITC-dextran leakage was delayed in fully confluent tubules cultured for 6 days, indicating a functional epithelial barrier.
  • HepLoC showed stronger hepatocyte maturation than 3D organoids, with increased mature hepatocyte markers and functions: higher ALB and HNF4A expression, detectable albumin and AAT secretion, and enhanced urea synthesis and ammonia elimination, approaching primary hepatocytes.
  • HepLoC formed functional bile canaliculi: CDF accumulated between cell junctions in HepLoC but largely stayed inside LoC, and TEM showed larger tight junctions and bile canaliculi in HepLoC.
  • Troglitazone induced dose-dependent hepatocyte injury with decreased viability, increased LDH, MRP2 and ZO-1 mislocalization, impaired bile acid transport, and tight-junction disruption; free fatty acids caused lipid droplet accumulation, increased triglycerides and ROS, and upregulated TNFA and IL6 while largely preserving viability.
  • In the screening application, reference hepatotoxins and LNP components were discriminated by viability assays; DSPE-PEG 2000 was biocompatible, DOTAP chloride was hepatotoxic, and D-Lin-MC3-DMA was safe at therapeutically relevant concentrations but toxic at higher doses. Curcumin liposomes reduced lipid accumulation more effectively than free curcumin with minimal hepatotoxicity.

Methods

  • Human liver organoids were established from healthy human liver tissue, expanded in Matrigel/Ultimatrix, then seeded as single cells into the upper perfusion channels of a 3-lane OrganoPlate with collagen I in the central channel; chips were cultured under dynamic flow on an OrganoFlow system.
  • Hepatocyte differentiation used a 2-step protocol: 1 week in BMP7-supplemented expansion medium followed by 1 week in hepatocyte differentiation medium containing factors including EGF, HGF, A83-01, DAPT, dexamethasone, BMP7, and FGF19.
  • Main analyses included immunofluorescence, ELISA, urea and ammonia assays, FITC-dextran barrier testing, CDFDA-based bile canaliculi imaging, TEM, qRT-PCR, RNA-seq/GSEA, ROS staining, and PrestoBlue viability assays for drug and nanoparticle screening.

Limitations

  • The paper states that HepLoC is “primarily” parenchymal-cell based and therefore a simplified version of the complex liver microenvironment; it says future versions should add non-parenchymal cells such as hepatic stellate cells and Kupffer cells.
  • The paper states that HepLoC still does not reach primary hepatocyte levels for some functions, and that further differentiation protocols need to be developed.
  • Evident from the text: the paper uses healthy donor liver tissue and models early-stage MAFLD and cholestasis in vitro, so it does not directly test advanced disease, patient-specific disease variation, or in vivo outcomes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12951-026-04477-0

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

7 Valid · 2 Not valid · 2 Not checked · 127 Own results and interpretations

78 more claims

Create a free account to see all 138 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 49

Create a free account to see these claims.

Citations

Cites

Show all 44 references

Cited by

See all 4

Metadata

Authors
Kong, D., Yu, S., Heegsma, J., Blokzijl, T., Qin, T., Pan, Y., Blokzijl, H., de Meijer, V. E., Duan, Y., Faber, K. N., Xia, Q., & He, K.
Affiliations
  • University Medical Center Groningen (NL)
  • Shanghai Jiao Tong University (CN)
Corresponding author
  • Kong, Defu
  • Faber, Klaas Nico
  • Xia, Qiang
  • He, Kang
Venue
Journal of nanobiotechnology
Published
2026-05-02
Volume
24
Issue
1
ISSN
1477-3155 (ISSN-L)
OpenAlex
W7160001015
Cited by
4
References
44
Citations by year
2026: 4
FWCI
5.98
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Nanobiotechnology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Shanghai Natural Science Foundation (23ZR1438600)
  • Shanghai Research Center for Organ Transplantation, Category A Key Research Center of Shanghai Municipality (2022ZZ01016)
  • Dynamic Evolution and Regulatory Mechanisms of Host Immune Response Before and After Liver Transplantation
  • Special Program of the National Natural Science Foundation of China (82241221)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
Keywords
liver-on-a-chip, organoids, hepatocyte differentiation, drug-induced liver injury, cholestatic liver injury, non-alcoholic fatty liver disease, free fatty acids, lipid droplets, hepatotoxicity screening, nanotherapeutics, MRP2, tight junction disruption, bile canaliculi, high-throughput screening
MeSH terms
Troglitazone, Multidrug Resistance-Associated Protein 2, Microphysiological Systems, Cell Differentiation, Drug Evaluation, Preclinical, Humans, Liver, Liver Diseases, Organoids, Hepatocytes, Microfluidics, Nanomedicine, Chemical and Drug Induced Liver Injury, High-Throughput Screening Assays

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-throughput human microfluidic organoid-on-a-chip platform for modeling liver diseases and screening nanotherapeutics. https://app.cochat.ai/papers/10.1186/s12951-026-04477-0
The paper
Kong, D., Yu, S., Heegsma, J., Blokzijl, T., Qin, T., Pan, Y., Blokzijl, H., de Meijer, V. E., Duan, Y., Faber, K. N., Xia, Q., & He, K. (2026). High-throughput human microfluidic organoid-on-a-chip platform for modeling liver diseases and screening nanotherapeutics. Journal of nanobiotechnology. https://doi.org/10.1186/s12951-026-04477-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.